Ardelyx (NASDAQ:ARDX) Reaches New 52-Week Low – Here’s What Happened

Ardelyx, Inc. (NASDAQ:ARDX)’s stock price reached a new 52-week low during trading on Monday. The company traded as low as $3.05 and last traded at $3.0950, with a volume of 237,969 shares changing hands. The stock had previously closed at $3.09.

Key Headlines Impacting Ardelyx

Here are the key news stories impacting Ardelyx this week:

• Positive Sentiment: Wedbush maintained an Outperform rating on Ardelyx, although it reduced its price target to $8 from $9. The target still implies substantial upside from recent levels, providing a supportive signal despite the cautious adjustment. Wedbush cuts price target on Ardelyx
• Neutral Sentiment: Ardelyx will report third-quarter 2026 financial results on November 3. Investors will focus on sales of IBSRELA and XPHOZAH, patient starts, payer access issues and management’s outlook for growth. The previous quarter included 34.3% year-over-year revenue growth but an EPS loss that was worse than analysts expected. Ardelyx to report third-quarter 2026 financial results
• Negative Sentiment: Multiple law firms publicized a securities class action covering investors who purchased Ardelyx shares from January 13, 2025 through August 6, 2026. The allegations claim Ardelyx overstated the commercial performance and growth prospects of IBSRELA and XPHOZAH while payer prior-authorization and step-edit restrictions slowed new-patient starts. The lead-plaintiff deadline is November 16, 2026. These are allegations, and the lawsuit could create legal costs, reputational risk and additional uncertainty around the company’s sales outlook. Ardelyx securities class action deadline alert

Analyst Ratings Changes

Several research firms have weighed in on ARDX. HC Wainwright restated a “buy” rating and issued a $13.00 price target on shares of Ardelyx in a research note on Friday, August 7th. Wedbush reiterated an “outperform” rating and set a $9.00 price objective on shares of Ardelyx in a research report on Tuesday, August 18th. Zacks Research raised shares of Ardelyx from a “strong sell” rating to a “hold” rating in a report on Friday, October 16th. Weiss Ratings restated a “sell (e+)” rating on shares of Ardelyx in a research report on Friday, September 25th. Finally, BTIG Research cut their target price on shares of Ardelyx from $17.00 to $14.00 and set a “buy” rating for the company in a research note on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $13.90.

Ardelyx Price Performance

The firm has a market cap of $799.89 million, a P/E ratio of -14.59 and a beta of 0.68. The company has a debt-to-equity ratio of 1.69, a current ratio of 3.34 and a quick ratio of 3.15. The stock’s 50-day simple moving average is $3.57 and its two-hundred day simple moving average is $4.97.

Ardelyx (NASDAQ:ARDX) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). The business had revenue of $120.88 million for the quarter, compared to analysts’ expectations of $121.03 million. Ardelyx had a negative net margin of 12.35% and a negative return on equity of 36.00%. Ardelyx’s revenue was up 34.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.08) EPS. Equities research analysts forecast that Ardelyx, Inc. will post -0.20 earnings per share for the current fiscal year.

Insider Activity at Ardelyx

In other Ardelyx news, insider Eric Foster sold 8,562 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $3.86, for a total value of $33,049.32. Following the completion of the sale, the insider directly owned 409,410 shares in the company, valued at $1,580,322.60. This trade represents a 2.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Mike Kelliher sold 7,758 shares of the business’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $3.86, for a total value of $29,945.88. Following the transaction, the insider owned 349,660 shares in the company, valued at approximately $1,349,687.60. This trade represents a 2.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 126,059 shares of company stock valued at $486,588 over the last 90 days. Insiders own 5.30% of the company’s stock.

Hedge Funds Weigh In On Ardelyx

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in Ardelyx in the 2nd quarter worth approximately $119,874,000. Jupiter Topco LLC purchased a new position in shares of Ardelyx during the 2nd quarter valued at approximately $27,043,000. AIGH Capital Management LLC purchased a new position in shares of Ardelyx during the 2nd quarter valued at approximately $16,320,000. Bank of America Corp DE increased its holdings in shares of Ardelyx by 5.8% during the 1st quarter. Bank of America Corp DE now owns 2,336,994 shares of the biopharmaceutical company’s stock valued at $13,999,000 after purchasing an additional 128,301 shares in the last quarter. Finally, Eversept Partners LP lifted its stake in shares of Ardelyx by 30.0% in the 1st quarter. Eversept Partners LP now owns 2,229,446 shares of the biopharmaceutical company’s stock valued at $13,354,000 after purchasing an additional 514,317 shares during the period. Hedge funds and other institutional investors own 58.92% of the company’s stock.

About Ardelyx

Ardelyx, Inc is a biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal and cardiorenal conditions. The company’s products are designed to act locally in the gastrointestinal tract to address diseases involving phosphate, sodium, and other electrolytes.

Ardelyx’s primary products include XPHOZAH (tenapanor), an oral treatment approved in the United States to reduce intestinal phosphate absorption in adults with chronic kidney disease on dialysis who have hyperphosphatemia, and IBSRELA (tenapanor), an oral therapy approved for the treatment of irritable bowel syndrome with constipation in adults.